
|Articles|August 28, 2015
New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
3
Pharmacy Policy Updates for October 2025
4
Expert: Tariff Increases May Pressure Pharmacy Margins and Supply Chains
5